A Phase Ia Clinical Study of QLF31907 Injection in Patients With Advanced Malignant Tumors

Summary

This study is designed to evaluate the safety and tolerability of QLF31907 injection, to identify the maximum tolerated dose (MTD) and dose-limiting toxicity(DLT), and determine the recommended phase Ib dose(RPIbD) and recommended phase II dose (RP2D)in patients with advanced malignant tumors.

Timeline

Start

2021-10-19

Primary completion

2024-03-31

Completion

2024-06-01

Drugs

Indications